Trial Profile
A Phase Ib/II Study of IV Nivolumab and Intrapleural Talimogene Laherparepvec for Patients With Malignant Pleural Effusion
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Apr 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Cancer; Malignant pleural effusion
- Focus Adverse reactions; Therapeutic Use
- 25 Mar 2021 Status changed from recruiting to discontinued.
- 16 May 2019 Status changed from not yet recruiting to recruiting.
- 07 Mar 2019 Planned initiation date changed from 1 Feb 2019 to 1 Mar 2019.